000007992 001__ 7992
000007992 005__ 20240124114256.0
000007992 0247_ $$2DOI$$a10.6083/8336h247h
000007992 037__ $$aETD
000007992 245__ $$aAnother brick in the wall: building epidemiologic evidence of infectious risks by psoriasis therapy types
000007992 260__ $$bOregon Health and Science University
000007992 269__ $$a2020
000007992 336__ $$aDissertation
000007992 502__ $$bPh.D.
000007992 502__ $$gEpidemiology
000007992 520__ $$aPsoriasis is a chronic, inflammatory disease that affects about 10 million individuals in the United States. New psoriasis treatments target the dysregulated immune system functions responsible for disease pathogenesis. However, many of these immune pathways are also responsible for protecting the body from fungal and bacterial infections. Due to the increasing number of biologic therapies recently approved to treat psoriasis, understanding the comparative infectious risk associated with different biologic therapies is of upmost importance.
000007992 542__ $$fIn copyright - single owner
000007992 650__ $$aPsoriasis$$024818
000007992 650__ $$aPatient Safety$$039887
000007992 650__ $$aInfections$$020790
000007992 6531_ $$abiologic therapy
000007992 691__ $$aOHSU-PSU School of Public Health$$041366
000007992 7001_ $$aRosenstein Siegel, Sarah A.
000007992 8564_ $$97bfe2336-9e4f-49da-b740-03808faefbd4$$s4296529$$uhttps://digitalcollections.ohsu.edu/record/7992/files/Siegel.Sarah.2020.pdf
000007992 905__ $$a/rest/prod/83/36/h2/47/8336h247h
000007992 909CO $$ooai:digitalcollections.ohsu.edu:7992$$pstudent-work
000007992 980__ $$aTheses and Dissertations
000007992 980__ $$aDual Author Affiliations Cleanup